Newburyport (MA, USA) – Access to comprehensive Next Generation Sequencing (NGS) kits for HIV Whole Genome genotyping is now available in the United States. AdvancedDx Biological Laboratories USA Inc., the US affiliate of ABL Diagnostics, a French company listed on the Euronext stock exchange, has announced the launch of DeepChek® Assay Whole Genome HIV-1 Genotyping.
This new assay is compatible with leading NGS platforms and offers optimized PCR master mixes and primers for amplifying RNA and DNA inputs. The comprehensive kit allows for the screening of mutations in all HIV-1 genomic targets related to current and developing HIV-1 inhibitors, including new drugs like lenacapavir and cabenuva.
The DeepChek® Assay is intended for use in discovering and developing medical knowledge related to HIV-1 mutations and their potential impact on drug resistance. By analyzing the genetic sequences of HIV-1, researchers can monitor and control the virus’s evolution, build databases linking mutation patterns and treatment response, and identify drug-resistant viruses to prevent transmission.
“We are excited to offer this comprehensive kit to researchers and public health initiatives in the US,” said Dimitri Gonzalez, Head of Sales & Marketing at AdvancedDx Biological Laboratories USA Inc. “There is a growing trend for microbiology laboratories to implement NGS-based technologies alongside traditional sequencing methods, and our kit can support these efforts.”
ABL Diagnostics, the parent company of AdvancedDx Biological Laboratories USA Inc., offers a range of Research Use Only kits for NGS and Sanger sequencing platforms. These kits include general laboratory reagents for diverse sequencing methods and sample types, as well as library preparation reagents and universal adapters for NGS.
The sequencing outputs can be analyzed with specific downstream sequencing analysis software such as DeepChek® Software, or with generic bioinformatics software for more advanced research teams.
For further information about ABL Diagnostics and its products, please visit www.abldx.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.